Rigel Pharmaceuticals, Inc. RIGL
Set alert
50.41 USD -0.13 -0.25%
As of Nov 3, 10:21 AM ET
50.04 Day range 51.29
24.95 52-week range 52.61
- YTD
- +17.69%
- 1 year
- +64.45%
- Open
- 50.44
- Prev close
- 50.53
- Mkt cap
- 932.69M
- Vol
- 63.10K
- Avg vol
- 259.24K
- EPS
- 16.88
- P/E
- 2.99
- Div yield
- 0.00%
More statistics
- Low
- 50.04
- High
- 51.29
- Forward P/E
- 19.49
- Beta
- 0.95
- Short ratio
- 1.69
- Inst. own
- 68.01%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 20.01
- 200-d avg
- 13.77
- 1y target
- 31.33
Analyst view
Consensus: buy
Buy
Price target (mean) 31.33 -37.8% downside
Now 50.41
- Target (low)
- 14.00
- Target (mean)
- 31.33
- Target (high)
- 57.00
Ratings (0m) 6 2 buy · 4 hold · 0 sell
- Strong buy1
- Buy1
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.33401 | 0.13 – 0.59 | 0.00 | 0.0% | 47.42M | +32.5% | 5 |
| Next quarter | 0.18 | 0.18 – 0.18 | -0.50 | +136.0% | 43.49M | +47.3% | 1 |
| Current year | 0.24086 | 0.09 – 0.37 | -1.40 | +117.2% | 169.10M | +44.7% | 5 |
| Next year | 1.04 | 0.53 – 1.61 | 0.24086 | +331.4% | 193.51M | +14.4% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Cantor Fitzgerald | Maintained | Neutral | Neutral |
| Dec 10, 2024 | B. Riley Securities | Maintained | Neutral | Neutral |
| Dec 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 6, 2024 | B. Riley Securities | Maintained | Neutral | Neutral |
| Nov 14, 2024 | Piper Sandler | Maintained | Neutral | Neutral |
| Nov 12, 2024 | Citigroup | Maintained | Buy | Buy |
| Oct 25, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 9, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 25, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 3, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 7, 2024 | Citigroup | Maintained | Buy | Buy |
| Mar 6, 2024 | Cantor Fitzgerald | Maintained | Neutral | Neutral |
| Mar 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 6, 2024 | B. Riley Securities | Maintained | Neutral | Neutral |
| Feb 22, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 8, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 2, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 3, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 9, 2023 | Citigroup | Maintained | — | Buy |
| Mar 8, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Dec 2, 2022 | Citigroup | Upgrade | Neutral | Buy |
| Nov 4, 2022 | BMO Capital | Maintained | — | Outperform |
| Aug 18, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 17, 2022 | Piper Sandler | Maintained | — | Neutral |
| Jun 9, 2022 | BMO Capital | Maintained | — | Outperform |
| Jun 9, 2022 | B. Riley Securities | Maintained | — | Neutral |
| Jun 9, 2022 | Citigroup | Downgrade | Buy | Neutral |